Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

in response to

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

tada

posted on Jan 26, 2023 07:55PM

Payzone - Actually thinking back to the AGM, DM did say that Merck was getting excited about the results in our trial because up until now(Oct 2022) they were not having much success with Keytruda in prostate cancer. By haulting that trial it may be a very good sign for ZEN-3694. It will be interesting to see if a PIII trial is being planned for the combination of Keytruda, Xtandi and ZEN-3694.